Late Medical Complications and Fatigue in Hodgkin’s Disease Survivors

Knobel, Heidi; Loge, Jon Håvard; Lund, May Brit; Forfang, Kolbjørn; Nome, Ole; Kaasa, Stein

doi:10.1200/jco.2001.19.13.3226

Cited by 113 publications

(64 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As in the paper by Knobel et al, 31 most of them were endocrine or general symptoms, confirming that causes of chronic fatigue are highly prevalent among HL survivors. We were also able to individualize a 5% cumulative incidence of respiratory and cardiac late toxicities, which is rather high in this 32-year-old median age population, although left ventricular function and respiratory functions were not systematically assessed.…”

Section: Discussionsupporting

confidence: 60%

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Fermé

Mounier

Casasnovas

et al. 2006

Blood

View full text Add to dashboard Cite

From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n ‫؍‬ 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n ‫؍‬ 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n ‫؍‬ 208) or subtotal nodal irradiation (RT) (n ‫؍‬ 210). A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for AB-VPP؋8, 78% for MOPP/ABV؋8, 82% for MOPP/ABV with RT, and 77% for AB-VPP؋6 with RT (P ‫؍‬ .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79%, and 76%, respectively (P ‫؍‬ .09). The 10-year DFS estimates for patients treated with consolidation CT or RT were 73% and 78% (P ‫؍‬ .07), and OS estimates were 84% and 79%, respectively (P ‫؍‬ .29). These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL. An analysis of competing risks identified age more than 45 years as a significant risk factor for death, relapse, and second cancers.

show abstract

Section: Discussionsupporting

confidence: 60%

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Fermé

Mounier

Casasnovas

et al. 2006

Blood

View full text Add to dashboard Cite

show abstract

“…43,44,45 In agreement with our findings, thyroid disorders are often described among survivors of lymphoma, probably due to mantle field irradiation. 46,47 Surprisingly, a higher prevalence of thyroid disease among TCSs in comparison to the controls was found. In Norway in the 1980s, radiation to the left or both supraclavicular fossae was standard when treating seminomatous testicular cancer with regional lymph node metastases, 48 which may explain the results.…”

Section: Discussionmentioning

confidence: 89%

Self‐reported health and use of health care services in long‐term cancer survivors

Nord

Mykletun

Thorsen

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Owing to an increasing number of long-term cancer survivors, the use of health care services and somatic health problems were compared between cancer survivors and a noncancer population. Data from the Nord-Trøndelag Health Survey 2 (HUNT 2, 1995-1997) was merged with the Cancer Registry of Norway. Six cancer subgroups were constructed with diagnosis 5 years prior HUNT 2: testicular cancer (n‫؍‬ 59), colorectal cancer (n‫؍‬ 175), prostate cancer (n‫؍‬ 87), breast cancer (n‫؍‬ 258), gynaecological cancer (n‫؍‬ 153) and lymphoma/leukaemia (n‫؍‬ 83). For each cancer survivor 3 matched noncancer controls were selected from the HUNT 2 survey. The prevalence of common health problems, use of health care services and unfavourably life style parameters were compared between the 2 groups. Cancer survivors used health care services and received social welfare benefits more often than the controls. There was an increased risk of perceiving poor health after a history of cancer. In the recent decade, the incidence of most malignancies has increased, as well as 5-year survival rates in both men and women. 1 During 1992-1996, the relative overall 5-year survival rate for all cancer patients in Norway was, respectively, 50% in males and 58%; in females compared to 25% in males and 38%; in females for the period 1957-1961. In 1999, a total of 83,636 cancer survivors with an at-least 5-year survival were alive in Norway. 1 These figures have in the last few years led to a paradigm shift: cancer should not only be considered an acute or terminal event but should likewise be viewed as a chronic condition. Quality of life and long-term effects after cancer therapy have therefore become important outcome parameters to be considered by oncologists, cancer surgeons and primary health care officers.Cancer represents a heterogeneous group of diagnoses where treatment and aetiology are far from uniform. The cancer itself and its treatment may affect the long-term health of cancer survivors at various degrees, causing adverse health conditions, which differ from those observed in the age-matched noncancer population. The recognition of common health problems reducing the overall well being among cancer survivors is of importance in order to identify these individuals' specific needs when presented to the health care service. Furthermore the recognition of long-term effects of treatment may lead to reconsideration and eventual modification of current treatment strategies.Several reports have focused on long-term medical effects after treatment for childhood cancer as well as adulthood cancer and have described specific health problems related to different treatment modalities. 2,3,4 -9 Beside causing chronic health conditions, cancer and its treatment increase the risk of secondary malignancies. 10 -13 Owing to the increased risk of developing secondary tumours and chronic diseases after treatment for malignancies, cancer survivors represent an important target population for health promotion interventions. Few studies regarding long-te...

show abstract

“…Fatigue is one of the most frequently reported symptoms among long-term Hodgkin's lymphoma survivors. 38 The prevalence of chronic fatigue ranges from 25% to 30%, compared to 12% of the general population. 39 It is common even many years after diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: A population-based study

Mols

Vingerhoets

Coebergh

et al. 2006

European Journal of Cancer

View full text Add to dashboard Cite

Late Medical Complications and Fatigue in Hodgkin’s Disease Survivors

Abstract: Pulmonary dysfunction is associated with fatigue in HDSs. Cardiac sequelae was not associated with fatigue in HDSs. We question the absence of an association between thyroid complications and fatigue.

Cited by 113 publications

References 48 publications

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Self‐reported health and use of health care services in long‐term cancer survivors

Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: A population-based study

Contact Info

Product

Resources

About